CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cypress Bioscience, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cypress Bioscience, Inc.
Suite 325, 4350 Executive Drive
Phone: (858) 452-2323p:858 452-2323 SAN DIEGO, CA  92121  United States

This company ceased filing statements with the SEC on 1/14/2011.
As of 3/1/2023, the Company is a part of Cowen Inc, which is owned by Toronto-Dominion Bank.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Cypress Bioscience, Inc. provides therapeutics and personalized medicine services, facilitating improved and individualized patient care. The Company focuses on addressing the evolving needs of specialist physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders, such as fibromyalgia and rheumatoid arthritis. In January 2009, the Company received approval from the United States Food and Drug Administration (FDA) to market Savella (milnacipran HCl) for the management of fibromyalgia (FM). In February 2009, it announced the closing of a transaction to acquire Cellatope Corporation’s technology platform. Technology platform uses cell-bound complement activation products (CB-CAP) to diagnose and monitor debilitating autoimmune disorders, including lupus.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201012/31/2009YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Jay D.Kranzler 54 4/1/1998 12/1/1995
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Corporate Secretary Sabrina M.Johnson 46 1/25/2008 10/1/2000
Chief Scientific Officer, Director of Science and Technology Srinivas G.Rao 45 1/1/2001
6 additional Officers and Directors records available in full report.

General Information
Stock Exchange: NASD
Federal Tax Id: 222389839
Email Address: investorrelations@cypressbio.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023